PSDV - pSivida Corp.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

pSivida Corp.

480 Pleasant Street
Suite B300
Watertown, MA 02472
United States

IndustryDrugs - Generic
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Ms. Nancy S. LurkerPres, CEO & DirectorN/AN/A1957
Mr. Leonard S. RossVP of Fin., Chief Accounting Officer & Principal Financial OfficerN/AN/A1950
Ms. Deborah A. JornExec. VP of Corp. & Commercial Devel.N/AN/A1958
Dr. Dario A. Paggiarino M.D.VP & Chief Medical OfficerN/AN/A1957
Mr. Marty NazzaroSr. VP of OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. It is also developing Durasert, which is in pre-clinical trials for the treatment of posterior segment uveitis; steroid implant for severe knee osteoarthritis; and TKI Insert, an injectable, bioerodible, sustained-release Durasert insert delivering a tyrosine kinase inhibitor for treatment of wet age-related macular degeneration. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Nicox S.A. pSivida Corp. was founded in 1987 and is based in Watertown, Massachusetts.

Corporate Governance

pSivida Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.